Pre-order Enquiry
Request Free Sample
Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Insights and Forecast to 2028
SKU ID : QYR-20512920 | Publishing Date : 15-Mar-2022 | No. of pages : 96
Request Sample
Request Customization
Check DiscountsDetailed TOC of Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Insights and Forecast to 2028
1 Study Coverage1.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Introduction
1.2 Market by Type
1.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 1g/20ml
1.2.3 1.25g/25ml
1.2.4 2.5g/50ml
1.2.5 5g/100ml
1.2.6 10g/200ml
1.3 Market by Application
1.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Estimates and Forecasts 2017-2028
2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Estimates and Forecasts 2017-2028
2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region
2.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022)
2.4.2 Global Sales Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2023-2028)
2.5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region
2.5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022)
2.5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers
3.1.1 Global Top Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers by Sales (2017-2022)
3.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in 2021
3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers
3.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022)
3.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021
3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type
4.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Type (2017-2022)
4.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Type (2023-2028)
4.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type
4.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Type (2017-2022)
4.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Type (2023-2028)
4.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type
4.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022)
4.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application
5.1.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Sales by Application (2017-2022)
5.1.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Sales by Application (2023-2028)
5.1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application
5.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historical Revenue by Application (2017-2022)
5.2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Forecasted Revenue by Application (2023-2028)
5.2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application
5.3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022)
5.3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028)
6 North America
6.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
6.1.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
6.1.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
6.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
6.2.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
6.2.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
6.3 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
6.3.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
6.3.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
7.1.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
7.1.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
7.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
7.2.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
7.2.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
7.3 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
7.3.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
7.3.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
8.1.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
8.1.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
8.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
8.2.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
8.2.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
8.3 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region
8.3.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2028)
8.3.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
9.1.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
9.1.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
9.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
9.2.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
9.2.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
9.3 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
9.3.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
9.3.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Type
10.1.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2028)
10.1.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2028)
10.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Application
10.2.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2028)
10.2.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2028)
10.3 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Country
10.3.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2028)
10.3.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Boya-Bio
11.1.1 Boya-Bio Corporation Information
11.1.2 Boya-Bio Overview
11.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Boya-Bio Recent Developments
11.2 Beijing Tiantan Biological Products
11.2.1 Beijing Tiantan Biological Products Corporation Information
11.2.2 Beijing Tiantan Biological Products Overview
11.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Beijing Tiantan Biological Products Recent Developments
11.3 Hualan Bio
11.3.1 Hualan Bio Corporation Information
11.3.2 Hualan Bio Overview
11.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Hualan Bio Recent Developments
11.4 Guangdong Shuagnlin Bio-pharmacy
11.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
11.4.2 Guangdong Shuagnlin Bio-pharmacy Overview
11.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
11.5 Weiguang Biological
11.5.1 Weiguang Biological Corporation Information
11.5.2 Weiguang Biological Overview
11.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Weiguang Biological Recent Developments
11.6 Sinopharm
11.6.1 Sinopharm Corporation Information
11.6.2 Sinopharm Overview
11.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Sinopharm Recent Developments
11.7 Shanghai RAAS
11.7.1 Shanghai RAAS Corporation Information
11.7.2 Shanghai RAAS Overview
11.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Shanghai RAAS Recent Developments
11.8 CTBB
11.8.1 CTBB Corporation Information
11.8.2 CTBB Overview
11.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CTBB Recent Developments
11.9 Nanyue Biopharming
11.9.1 Nanyue Biopharming Corporation Information
11.9.2 Nanyue Biopharming Overview
11.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Nanyue Biopharming Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Chain Analysis
12.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Mode & Process
12.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Marketing
12.4.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Channels
12.4.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors
12.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Trends
13.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers
13.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges
13.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints
14 Key Findings in The Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figures, Tables and Charts Available in Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Insights and Forecast to 2028
List of TablesTable 1. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 1g/20ml
Table 3. Major Manufacturers of 1.25g/25ml
Table 4. Major Manufacturers of 2.5g/50ml
Table 5. Major Manufacturers of 5g/100ml
Table 6. Major Manufacturers of 10g/200ml
Table 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units)
Table 10. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)
Table 11. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units)
Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2023-2028)
Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2017-2022)
Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2023-2028)
Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers (2017-2022)
Table 19. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2017-2022)
Table 21. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Manufacturers (2017-2022) &(US$/Unit)
Table 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) as of 2021)
Table 24. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offered
Table 26. Date of Manufacturers Enter into Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 29. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 30. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2017-2022)
Table 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Type (2023-2028)
Table 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2017-2022)
Table 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2023-2028)
Table 36. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2017-2022) & (US$/Unit)
Table 37. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Type (2023-2028) & (US$/Unit)
Table 38. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 39. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 40. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2017-2022)
Table 41. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Application (2023-2028)
Table 42. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2017-2022)
Table 45. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2023-2028)
Table 46. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2017-2022) & (US$/Unit)
Table 47. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price Forecast by Application (2023-2028) & (US$/Unit)
Table 48. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 49. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 50. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 53. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 54. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 57. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 58. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 61. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 62. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 65. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 66. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 69. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 70. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2023-2028) & (US$ Million)
Table 108. Boya-Bio Corporation Information
Table 109. Boya-Bio Description and Major Businesses
Table 110. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 111. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Boya-Bio Recent Developments
Table 113. Beijing Tiantan Biological Products Corporation Information
Table 114. Beijing Tiantan Biological Products Description and Major Businesses
Table 115. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 116. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Beijing Tiantan Biological Products Recent Developments
Table 118. Hualan Bio Corporation Information
Table 119. Hualan Bio Description and Major Businesses
Table 120. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 121. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Hualan Bio Recent Developments
Table 123. Guangdong Shuagnlin Bio-pharmacy Corporation Information
Table 124. Guangdong Shuagnlin Bio-pharmacy Description and Major Businesses
Table 125. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 126. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Guangdong Shuagnlin Bio-pharmacy Recent Developments
Table 128. Weiguang Biological Corporation Information
Table 129. Weiguang Biological Description and Major Businesses
Table 130. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 131. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Weiguang Biological Recent Developments
Table 133. Sinopharm Corporation Information
Table 134. Sinopharm Description and Major Businesses
Table 135. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 136. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Sinopharm Recent Developments
Table 138. Shanghai RAAS Corporation Information
Table 139. Shanghai RAAS Description and Major Businesses
Table 140. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 141. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Shanghai RAAS Recent Developments
Table 143. CTBB Corporation Information
Table 144. CTBB Description and Major Businesses
Table 145. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 146. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. CTBB Recent Developments
Table 148. Nanyue Biopharming Corporation Information
Table 149. Nanyue Biopharming Description and Major Businesses
Table 150. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 151. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Nanyue Biopharming Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
Table 156. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers List
Table 157. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Trends
Table 158. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers
Table 159. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges
Table 160. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Picture
Figure 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Type in 2021 & 2028
Figure 3. 1g/20ml Product Picture
Figure 4. 1.25g/25ml Product Picture
Figure 5. 2.5g/50ml Product Picture
Figure 6. 5g/100ml Product Picture
Figure 7. 10g/200ml Product Picture
Figure 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Application in 2021 & 2028
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Report Years Considered
Figure 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2017-2028 (K Units)
Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2017-2028 (US$ Million)
Figure 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2017-2022)
Figure 18. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2023-2028)
Figure 19. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units)
Figure 20. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in the World: Market Share by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021
Figure 31. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 33. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 34. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 35. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 36. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 37. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 38. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 39. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 40. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028)
Figure 41. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028)
Figure 42. U.S. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 45. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 46. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 47. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 48. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028)
Figure 49. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028)
Figure 50. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 51. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Region (2017-2028)
Figure 61. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 64. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 66. Taiwan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 70. Philippines Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 71. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 72. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 73. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 74. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 75. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028)
Figure 76. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028)
Figure 77. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 78. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 79. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 80. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Country (2017-2028)
Figure 85. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Country (2017-2028)
Figure 86. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 87. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 88. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (2017-2028) & (US$ Million)
Figure 89. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Value Chain
Figure 90. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Process
Figure 91. Channels of Distribution
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed
Keyplayers in Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Insights and Forecast to 2028
Boya-BioBeijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
